Metis Global Partners LLC Has $1.18 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Metis Global Partners LLC boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,320 shares of the medical equipment provider’s stock after purchasing an additional 665 shares during the period. Metis Global Partners LLC’s holdings in Hologic were worth $1,177,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC increased its stake in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares during the period. Nordea Investment Management AB increased its stake in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares during the period. Swedbank AB increased its stake in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after buying an additional 238,222 shares during the period. Finally, Barclays PLC increased its stake in shares of Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after buying an additional 231,578 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. UBS Group increased their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $85.77.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.88% of the company’s stock.

Hologic Stock Down 0.2 %

Shares of NASDAQ:HOLX opened at $63.27 on Tuesday. The business’s 50 day simple moving average is $68.98 and its two-hundred day simple moving average is $75.78. The firm has a market cap of $14.20 billion, a P/E ratio of 19.96, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $62.69 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.